Join over 2,000+ Investors
Register now and embark on your journey to informed and successful investing.
Corvus Pharmaceuticals Inc
CRVS | US
16.74
USD1.70
11.30%
CRVS | US
About Corvus Pharmaceuticals Inc
Sector
Healthcare
Industry
Biotechnology
Earnings date
30/06/2024
As of date
17/04/2026
Close
16.74
Open
16.89
High
17.18
Low
16.19
Corvus Pharmaceuticals Inc. a clinical stage biopharmaceutical company focuses on the development and commercialization of immuno-oncology therapies. Its lead product candidate is Mupadolimab (CPI-006) an anti-CD73 monoclonal antibody which is in Phase I/Ib clinical trial for non-small cell lung cancer and head and neck cancers. The company also develops CPI-818 a covalent inhibitor of ITK which is in Phase I/Ib clinical trial to treat patients with various malignant T-cell lymphomas as well as designed to inhibit the proliferation of certain malignant T-cells; and Ciforadenant (CPI-444) an oral small molecule antagonist of the A2A receptor that is in Phase II clinical trial for patients with advanced or refractory renal cell cancer. Its preclinical stage products include CPI-182 an antibody designed to block inflammation and myeloid suppression; and CPI-935 an adenosine A2B receptor antagonist to prevent fibrosis. Corvus Pharmaceuticals Inc. has a strategic collaboration with Angel Pharmaceuticals. Corvus Pharmaceuticals Inc. was incorporated in 2014 and is based in Burlingame California.
View LessCRVS | US
Risk
77.3
Sharpe
2.25
Luna's Score
64/100
Recommendation
Hold
Luna says (CRVS | US)
What's Working
Positive Momentum
Strength based on increasing price with high volume
High Current Volume and Positive 1-Day Return
Low Debt to Equity (< 0.25)
Low Debt to Asset (< 0.2)
Strong Sharpe Ratio (> 1.2)
What's not Working
High 6-Month Volatility (>65%)
Smallcap (300M - 2B USD)
High Market Beta (> 0.8)
Rich in Valuation (Price to Book > 8)
Volatility Signals
Bearish: Increased Volatility (6-month > 1-month volatility)
Risk Meter
10 days
69.2%1 month
77.3%3 months
341.5%6 months
245.9%Returns
Fundamental Ratios
PE
-
Fwd. PE
-
Price to book
8.80
Debt to equity
0.01
Debt to assets
0.01
Ent. to EBITDA
0.36
Ent. to rev.
-
PEG
-
Other Fundamentals
EBITDA
-23.27M
MarketCap
1.05B
MarketCap(USD)
1.05B
Div. yield
-
Op. margin
-
Erngs. growth
-
Rev. growth
-
Ret. on equity
-44.91
Short ratio
4.15
Short perc.
4.26
Market Sentiment (SMA and Price signals)
Short-term: Bullish (SMA10D > SMA1M)
Intermediate-term: Bearish (SMA1M < SMA3M)
Long-term: Bullish (SMA6M > SMA12M)
SMAs: Stock Price Trends
Range10D
3.03
Range1M
4.23
Range3M
19.88
Volumes: Market Activity
Rel. volume
2.04
Price X volume
42.14M
Peers
Diversifiers
Industry Comparison
| Parameter | Company | Industry | Indicator |
|---|---|---|---|
| Enterprise to EBITDA | 0.36 | - | Cheaper |
| Ent. to Revenue | - | - | - |
| PE Ratio | - | 41.03 | - |
| Price to Book | 8.80 | 15.55 | Cheaper |
| Dividend Yield | - | - | - |
| Std. Deviation (3M) | 341.46 | - | Riskier |
| Debt to Equity | 0.01 | -1.23 | Expensive |
| Debt to Assets | 0.01 | 0.25 | Cheaper |
| Market Cap | 1.05B | - | Emerging |
